GlassScriptPhysician profile
Jerome Marcos
NPI 1538462999
$6,183.22
in general payments reported to CMS, 2019-2025
30 companies · $592 in 2025
The $592 reported for 2025 was more than what 76% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,231 · 2022: $1,618 · 2023: $1,744 · 2025: $592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,039 · Travel and Lodging: $296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,038.60 |
| Travel and Lodging | $296.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,445.07 | 2021-2023 | Relistor |
| Medtronic, INC. | $912.14 | 2022-2023 | Intellis Adaptivestim, Vanta Adaptivestim, Accurian |
| Abbvie INC. | $815.64 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $356.92 | 2022-2025 | Breyanzi, Pomalyst |
| Abbott Laboratories | $284.75 | 2021-2025 | Infinity |
| Collegium Pharmaceutical, INC. | $279.94 | 2021-2023 | Xtampza |
| Biohaven Pharmaceuticals, INC. | $256.61 | 2021 | |
| Biodelivery Sciences International, INC. | $220.30 | 2021 | |
| Scilex Pharmaceuticals INC. | $198.01 | 2021-2023 | Ztlido |
| Arbor Pharmaceuticals, INC. | $156.59 | 2021-2022 | |
| Glaxosmithkline, LLC. | $124.99 | 2025 | Ojjaara |
| Biohaven Pharmaceutical Holding Company LTD. | $119.20 | 2022 | |
| Pfizer INC. | $114.98 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $113.24 | 2025 | Austedo Xr |
| Genzyme Corporation | $110.97 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $107.75 | 2021-2022 | |
| Redhill Biopharma INC. | $100.17 | 2021-2022 | |
| Grt US Holding, INC. | $79.80 | 2022 | |
| Boston Scientific Corporation | $63.32 | 2021-2022 | |
| Painteq LLC | $56.85 | 2023 | Painteq |
| Globus Medical, INC. | $50.45 | 2025 | Senza |
| Kowa Pharmaceuticals America, INC. | $36.77 | 2022-2023 | Seglentis |
| Merz Pharmaceuticals, LLC | $35.20 | 2023 | Xeomin |
| Lilly USA, LLC | $32.49 | 2023 | Emgality, Reyvow |
| Amgen INC. | $32.33 | 2023 | Tavneos |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Azurity Pharmaceuticals, INC. | $15.90 | 2023 | Horizant |
| Nalu Medical, INC. | $14.62 | 2021 | |
| Virtus Pharmaceuticals LLC | $13.68 | 2023 | Levorphanol Tartrate |
| Amneal Pharmaceuticals LLC | $13.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerome Marcos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.